GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » Cyclically Adjusted FCF per Share

TTNP (Titan Pharmaceuticals) Cyclically Adjusted FCF per Share : $-524.58 (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Titan Pharmaceuticals's adjusted free cash flow per share for the three months ended in Dec. 2024 was $-0.554. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-524.58 for the trailing ten years ended in Dec. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 20.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Titan Pharmaceuticals was 27.40% per year. The lowest was -4.30% per year. And the median was 19.00% per year.

As of today (2025-05-15), Titan Pharmaceuticals's current stock price is $4.76. Titan Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $-524.58. Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Titan Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Titan Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Titan Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,476.12 -985.47 -979.28 -680.67 -524.58

Titan Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -680.67 -641.62 -601.17 -566.24 -524.58

Competitive Comparison of Titan Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

Titan Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Titan Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.554/133.1571*133.1571
=-0.554

Current CPI (Dec. 2024) = 133.1571.

Titan Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201503 -338.833 99.621 -452.896
201506 -320.667 100.684 -424.091
201509 -301.500 100.392 -399.903
201512 -305.500 99.792 -407.641
201603 -349.167 100.470 -462.764
201606 2,252.667 101.688 2,949.791
201609 -469.333 101.861 -613.532
201612 -413.833 101.863 -540.971
201703 -522.667 102.862 -676.603
201706 -420.000 103.349 -541.137
201709 -612.333 104.136 -782.984
201712 -587.000 104.011 -751.489
201803 -176.167 105.290 -222.794
201806 -308.500 106.317 -386.383
201809 -381.000 106.507 -476.335
201812 -166.045 105.998 -208.590
201903 -197.818 107.251 -245.601
201906 -182.087 108.070 -224.357
201909 -130.231 108.329 -160.078
201912 -39.323 108.420 -48.295
202003 -37.986 108.902 -46.447
202006 -25.570 108.767 -31.304
202009 -23.871 109.815 -28.945
202012 -12.801 109.897 -15.510
202103 -5.657 111.754 -6.740
202106 -3.917 114.631 -4.550
202109 -4.588 115.734 -5.279
202112 -2.184 117.630 -2.472
202203 -5.530 121.301 -6.071
202206 -2.580 125.017 -2.748
202209 -2.562 125.227 -2.724
202212 -2.154 125.222 -2.290
202303 -2.529 127.348 -2.644
202306 -1.481 128.729 -1.532
202309 -2.443 129.860 -2.505
202312 -2.975 129.419 -3.061
202403 -0.719 131.776 -0.727
202406 -2.263 132.554 -2.273
202409 -0.758 133.029 -0.759
202412 -0.554 133.157 -0.554

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Titan Pharmaceuticals  (NAS:TTNP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Titan Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Executives
Seow Gim Shen 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd. 10 percent owner NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo director 1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey director 3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg director 710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi director 44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe director, officer: President and COO 400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong 10 percent owner NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar director, 10 percent owner, officer: Chief Executive Officer VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc other: Member of 10% owner group 1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers director 630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab director C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin director, officer: Executive Chairman C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg officer: See Remarks 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080